CLDX Stock — Celldex Therapeutics, Inc.

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 7, 2026

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 18.2 · elevated Equity put/call 0.71

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +21%

above

Price vs 50-day avg +6%

above

RSI (14) 50

neutral

MACD trend Negative

52-week position 77%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +5%

trailing

6-month return +45%

trailing

YTD return +31%

this year

Relative strength +39%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $34 › 200d $29 — 50d above 200d

Institutional flow Accumulating

38 of 231 funds reported for Jun 30 · net +676.2K sh shares · +6 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

9.76% of float · ▼ -1.0% MoM · 9.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

231 holders — near 3-yr high, broad support

Squeeze score 71

high risk · 0–100

Fundamentals

Fair

Revenue growth +88%

Y/Y

EPS growth −59%

Y/Y

Free cash flow $-213.7M

Balance sheet $28.9M

net cash

Quant / Vol

risk profile

Very High

Volatility 57%

annualized · 1-yr

Max drawdown −24%

past year

ATR 4.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+21% Bullish

Price vs 50-day avg

+6% Bullish

RSI (14)

50 Neutral

MACD trend

Negative Bearish

52-week position

77% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $34 › 200d $29 — 50d above 200d

Institutional flow Accumulating

38 of 231 funds reported for Jun 30 · net +676.2K sh shares · +6 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

9.76% of float · ▼ -1.0% MoM · 9.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

231 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $20 Now $36 · 77% 52-wk high $40

vs 200-day avg +21% vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Cash used in operating activities	$63.9M	fourth quarter of 2025	—
Countries in Phase 3 CSU program	43	EMBARQ-CSU1 and EMBARQ-CSU2	—
Patients enrolled in Phase 3 CSU program	1,939	EMBARQ-CSU1 and EMBARQ-CSU2	—
Shares outstanding	66.5M	as of December 31, 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CLDX Celldex Therapeutics, Inc. this stock	$2.79B	+31.3%	+87.8%	—	9.8%
ONC BeOne Medicines Ltd.	$477.60B	+7.3%	+22179.2%	971.9	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$124.46B	+8.2%	+46.2%	29.1	2.0%
REGN Regeneron Pharmaceuticals, Inc.	$72.88B	-9.8%	+20.8%	17.0	3.3%
ARGX Argenx SE	$54.57B	+3.7%	—	—	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

234

% held: 93.4%
Reported: 38 of 231
Top holder: WELLINGTON MANAGEMENT GRO…

Held Float

View

Held by Funds

Fund positions

230

View

Short & Settlement

Short Interest Falling

Shares short

7.7M

Days to cover: 9.1d
Change: -75.5K sh

View

Short Volume

Short vol %

69%

As of: Jul 28, 2026

Short Total

View

Fails to Deliver

FTD shares

10.0K

Value: $376.2K
As of: Jun 30, 2026

View

Off-Exchange

Off-exchange %

43.2%

Week of: May 4, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$1.5M

Net income (FY): $-258.8M
EPS diluted: $-3.90

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 15, 2026
This year: 9

View

Proposed Sales

Value

$121.2K

Shares: 4.2K
Filed: Dec 4, 2025

View

Earnings & Events

Earnings Calls

Last call

Apr 14, 2026

View

	5D	20D	120D	MTD	YTD
CLDX	+0.9%	+4.6%	+44.9%	-4.2%	+31.3%
SPY	-0.4%	+1.4%	+6.3%	-1.0%	+8.4%
vs SPY	+1.3%	+3.2%	+38.6%	-3.2%	+22.9%

CLDX · Celldex Therapeutics, Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance